Global Next Generation Cancer Diagnostic Devices Market Size By Type (Next Generation Sequencing, qPCR & Multiplexing), By Application (Biomarker Development, CTC Analysis), By Region, And Segment For...

lobal Next Generation Cancer Diagnostic Devices Market Report Description

The Global Next Generation Cancer Diagnostic Devices Market was valued at USD 8.3 billion in 2023 and is projected to surpass USD 17.6 billion by 2031, growing at a CAGR of 9.8% during the forecast period (2023–2031).

The market growth is fueled by the rising global cancer burden, increasing demand for early and accurate cancer diagnosis, and advancements in molecular diagnostics and AI-driven imaging tools. These next-generation devices enhance diagnostic precision, enable personalized treatment plans, and significantly improve survival rates. Additionally, the growing adoption of liquid biopsy, genetic profiling, and multi-omics-based diagnostics is accelerating market expansion.

Drivers

1. Rising Global Cancer Incidence

With over 19 million new cancer cases reported annually, the need for early detection technologies is more critical than ever. Next-generation diagnostic devices provide non-invasive and highly sensitive cancer detection, improving treatment outcomes.

2. Technological Advancements

The integration of AI, machine learning, and molecular imaging has revolutionized cancer diagnostics. Devices leveraging liquid biopsy, next-generation sequencing (NGS), and multi-modal imaging are driving market adoption.

3. Shift Toward Personalized Medicine

The trend toward precision oncology is boosting demand for diagnostics that provide actionable insights into genetic mutations, enabling targeted therapies and better prognostic assessments.

Restraints

1. High Cost of Advanced Diagnostics

Next-generation cancer diagnostic devices involve significant R&D and operational costs, making them expensive and limiting access in low-income regions.

2. Regulatory and Reimbursement Challenges

Complex regulatory pathways and inadequate reimbursement policies for advanced cancer diagnostics in many regions hinder widespread adoption.

Opportunities

1. Liquid Biopsy and Non-Invasive Testing

Liquid biopsies, which allow real-time tumor monitoring, present a huge growth opportunity as they reduce the need for invasive procedures.

2. Expansion in Emerging Markets

Developing nations with rising healthcare infrastructure and increasing awareness of early cancer detection create lucrative growth potential.

3. AI and Digital Pathology Integration

The convergence of AI-powered analytics with digital pathology platforms enhances diagnostic accuracy and reduces turnaround time, opening new market opportunities.

Market by System Type Insights

Molecular Diagnostics Devices held the largest market share in 2023, driven by the growing use of NGS platforms, PCR-based assays, and companion diagnostics for targeted therapies.

Imaging-Based Devices (AI-driven MRI, PET, and CT scanners) are expected to witness the fastest growth due to advancements in radiomics and deep-learning models.

Market by End-use Insights

Hospitals & Cancer Specialty Centers dominated the market in 2023 with over 45% share, driven by their access to advanced diagnostic tools and large patient pools.

Diagnostic Laboratories are expected to grow significantly, fueled by the increasing demand for outsourcing complex cancer diagnostic tests and the availability of high-throughput devices.

Market by Regional Insights

North America accounted for the largest market share in 2023 due to its advanced healthcare infrastructure, high adoption of AI-driven diagnostics, and strong presence of key market players.

Asia-Pacific is projected to witness the fastest growth during the forecast period, driven by the rising cancer prevalence, healthcare investments, and expanding genomic research initiatives in countries like China, India, and Japan.

Europe maintains a significant share owing to its strong regulatory frameworks and high awareness of cancer screening programs.

Competitive Scenario

Key players operating in the global next-generation cancer diagnostic devices market include:

Roche Diagnostics

Illumina, Inc.

Thermo Fisher Scientific

Abbott Laboratories

Siemens Healthineers

Bio-Rad Laboratories

Exact Sciences Corporation

Agilent Technologies

Guardant Health

Foundation Medicine, Inc.

These companies focus on product innovation, AI-based diagnostic integration, strategic collaborations, and acquisitions to strengthen their market positions.

Recent Developments:

In 2024, Roche launched its AI-driven liquid biopsy platform for real-time cancer monitoring.

Illumina partnered with a leading oncology center in 2023 to advance NGS-based companion diagnostics.

Thermo Fisher Scientific introduced a next-generation multi-omics cancer diagnostic device in 2025, enabling precision oncology at scale.

Scope of Work – Global Next Generation Cancer Diagnostic Devices Market

FAQs

1) What is the current market size of the Global Next Generation Cancer Diagnostic Devices Market?

The market was valued at USD 8.3 billion in 2023.

2) What is the major growth driver of the Global Next Generation Cancer Diagnostic Devices Market?

The market is primarily driven by rising cancer incidence and technological advancements in molecular diagnostics and AI-driven imaging solutions.

3) Which is the largest region during the forecast period in the Global Next Generation Cancer Diagnostic Devices Market?

North America is the largest region, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Next Generation Cancer Diagnostic Devices Market?

The Molecular Diagnostics Devices segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Next Generation Cancer Diagnostic Devices Market?

Key players include Roche Diagnostics, Illumina, Thermo Fisher Scientific, Abbott, Siemens Healthineers, and Guardant Health.

Would you like me to also create a visually appealing infographic summary of this report for quick presentation? Or prepare a PowerPoint-friendly version with key highlights?